UNH
UnitedHealth Group Incorporated
NYSE: UNH · HEALTHCARE · HEALTHCARE PLANS
$408.52
+0.73% today
Updated 2026-06-12
Market cap
$343.21B
P/E ratio
28.50
P/S ratio
0.76x
EPS (TTM)
$13.26
Dividend yield
2.33%
52W range
$230 – $404
Volume
8.0M
UnitedHealth Group Incorporated (UNH) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed UNH price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$408.52
Today
Analyst consensus
$407.38
-0.28% · 12M
2030 Base
$626.50
+53.36% future
NPV today
$439.21
@ 8% WACC
28 analysts:
21 Buy5 Hold1 Sell
Management guidance
UnitedHealth management has raised full-year 2026 guidance following strong Q1 2026 results, with the company demonstrating improved operational performance and earnings trajectory. Specific guidance: FY2026 revenue ~$444.4B (consensus), with management confidence in sustained earnings growth driven by Medical Care Ratio improvement and operational efficiency. No specific multi-year revenue targets beyond 2026 have been publicly stated by CEO Stephen Hemsley.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
UNH · UnitedHealth Group Incorporated · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$374.47
NPV today: $262.52
Base case (2030)
$626.50
NPV today: $439.21
Bull case (2030)
$1,193.57
NPV today: $836.76
WallStSmart.com
UNH financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $447.6B | $444.4B | $468.6B | $499.8B | $537.4B | $579.1B |
| Revenue growth | 11.8% | -0.7% | 5.5% | 6.7% | 7.5% | 7.8% |
| Net margin | — | 3.8% | 4.3% | 4.7% | 5.1% | 5.6% |
| EPS | $16.31 | $18.39 | $21.80 | $25.50 | $30.10 | $35.20 |
| Diluted shares | — | 911M | 914M | 915M | 917M | 919M |
| Net debt | — | $28.89B | $10.12B | $-9.90B | $-31.42B | $-54.62B |
| P/S multiple | — | 0.9x | 0.9x | 0.9x | 0.9x | 0.9x |
| Implied price (base) | — | $407.38 | $450.55 | $502.19 | $561.55 | $626.50 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $579.1B | $579.1B | $579.1B |
| P/S multiple | 0.5x | 0.9x | 1.8x |
| Diluted shares | 919M | 919M | 919M |
| Net debt | $-54.62B | $-54.62B | $-54.62B |
| Implied P/E † | 11x | 18x | 34x |
| 2030 Price | $374.47 | $626.50 | $1,193.57 |
| NPV @ 8% | $262.52 | $439.21 | $836.76 |
† Implied P/E: Multiples remain elevated across all three scenarios because UNH is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $626.50 base case
UNH catalysts and risks
Growth catalysts
+ Medicare Advantage membership growth and reimbursement optimization (favorable Q1 2026 trends noted by BofA and Morgan Stanley)
+ Optum health services platform scaling and AI-driven operational efficiency in cost containment
+ Medical cost trend moderation creating margin expansion opportunity (management raised FY2026 guidance on this)
+ Commercial and Medicaid market share gains amid competitor exits
+ AI efficiency gains in prior authorization, claims processing, and care coordination across Optum ecosystem
Key risks
- Regulatory/legislative headwinds on Medicare Advantage reimbursement rates and prior authorization restrictions
- Medical cost inflation acceleration if trend moderation reverses (2024 showed extreme volatility)
- Ongoing DOJ/state scrutiny of healthcare consolidation and pricing practices
- Berkshire Hathaway exit of entire UNH position (completed Q1 2026) signals activist skepticism on valuation/governance
- Competitive pressure from CVS Health and Cigna in integrated care model; Humana gaining momentum
Methodology · UnitedHealth Group Incorporated 2030 stock forecast model
UnitedHealth Group Incorporated 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 28 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (1% cumulative for UNH by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($-54.62B by 2030) |
| 3. Time value | NPV calculated using 8% WACC (CAPM: beta 0.646) |
| 4. Multiple framework | P/S compresses with scale: bear 0.5x / base 0.9x / bull 1.8x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: June 9, 2026.
UNH price target FAQ
What is the UNH price target for 2030?
WallStSmart's UnitedHealth Group Incorporated 2030 base case is $626.50 per share, with a bull case of $1,193.57 and bear case of $374.47. The NPV of the base case discounted to today at 8% WACC is $439.21.
How is the UnitedHealth Group Incorporated 2030 stock forecast calculated?
The UNH 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the UNH price target account for dilution?
UnitedHealth Group Incorporated is projected to grow diluted share count from 908M to 919M by 2030 (a 1% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 1%.
What is the analyst consensus on UNH stock?
28 analysts cover UNH with an average 12-month price target of $407.38. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.